KDR and gastroesophageal junction adenocarcinoma: Second-line treatment was associated with improved OS in esophagogastric adenocarcinoma (EGA).4,5 The most common treatment protocol combines the vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitor ramucirumab with paclitaxel.6